FOCUS ON: SCREENING
Monday 16 October 2006, 09:30–11:00

Screening for colon cancer

J P Heiken
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri, USA
Corresponding address: Jay P Heiken, MD, Mallinckrodt Institute of Radiology, 510 South Kingshighway Blvd., St Louis, MO 63110, USA. E-mail: heikenj@wustl.edu

Abstract
Colorectal cancer screening reduces mortality in individuals 50 years and older. Each of the screening tests currently available has advantages and limitations, and there is no consensus as to which test or combination of tests is best. What is clear, however, is that the rates of colorectal cancer screening remain low. This review summarizes the clinical evidence supporting colorectal cancer screening in the average risk population and in high risk groups, discusses the advantages and disadvantages of the available screening tests, outlines the currently recommended guidelines for screening based on risk category, and discusses new and emerging technologies for colorectal cancer screening.

Keywords: Neoplasms; polyps; colon; colonoscopy; rectum.

Introduction
Colorectal cancer is the third most common cancer throughout the world, with more than one million new cases diagnosed each year[1], and it is the second leading cause of cancer death in the United States. Last year in the United States alone, more than 145,000 people were diagnosed with colorectal cancer and more than 56,000 died of their disease[2]. Fortunately, this neoplasm is highly suited to screening because of its long preclinical phase, during which it is detectable and curable[3]. Nevertheless, screening programs for colorectal cancer have been only partly successful, owing largely to poor patient compliance with screening recommendations[4–7]. A number of organizations including the World Health Organization (WHO), the American Cancer Society (ACS), the US Agency for Health Care Policy and Research (USAHCPR), and the US Preventive Service Task Force (USPSTF) have issued or endorsed guidelines for colorectal cancer screening[8–10].

Average risk population
Average risk patients are asymptomatic individuals 50 years of age or older who have no personal or family history of colorectal cancer or adenomatous polyps and no history of inflammatory bowel disease. The most recently published screening recommendations of the ACS[8], the USAHCPR[9] and the USPSTF[10] present guidelines for screening average risk patients in the form of lists of options (Table 1). The options include annual (or biennial) fecal occult blood test, flexible sigmoidoscopy every 5 years, annual fecal occult blood test plus flexible sigmoidoscopy every 5 years, double contrast barium enema every 5 years, and colonoscopy every 10 years.

Fecal occult blood testing
Fecal occult blood testing (FOBT) is the safest and least expensive of the currently available screening tests. Three prospective, randomized, controlled trials have demonstrated the effectiveness of serial FOBT in reducing colorectal cancer mortality by 15%–33%[11–14]. However, its benefit in reducing colorectal mortality is attributed not only to early cancer detection but also to the incidental discovery and removal of adenomatous polyps at subsequent colonoscopy, which is recommended for patients with a positive FOBT. Such chance discovery of adenomatous polyps and non-bleeding cancers by colonoscopy has been estimated to account for 16%–25% of the colorectal cancer deaths prevented by the use of FOBT[15]. Nevertheless, one national study
showed that only one-third of individuals with a positive FOBT currently undergo colonoscopy\(^{[16]}\). Limitations of FOBT include its relatively low sensitivity for detecting cancers and its inability to detect the vast majority of adenomas\(^{[17]}\). Because colorectal cancers bleed intermittently, 50% or more of patients with colorectal cancer may have a negative test result\(^{[17,18]}\). Thus, to be effective, FOBT must be administered annually or biennially, which makes patient compliance a problem. Furthermore, the positive predictive value of standard FOBT is only approximately 10%\(^{[17,18]}\).

The most widely used test in the United States, Hemoccult II, is a guaiac-based test that detects the pseudoperoxidase activity found in hemoglobin after application of hydrogen peroxide to the stool sample. It requires that the patient apply to six test card windows two separate samples from three different stools. The test is not specific for human hemoglobin, and dietary substances can result in false positive and false negative examinations\(^{[19–21]}\). Rehydration of the test samples before applying hydrogen peroxidase to the test windows increases sensitivity, but is not recommended\(^{[9]}\) because it increases the false positive rate, thus reducing the positive predictive value by more than 50%\(^{[11]}\). Newer guaiac-based and immunochemical FOBT tests (see section on New and emerging technologies) have improved sensitivity with maintenance of acceptable specificity\(^{[22,23]}\).

### Flexible sigmoidoscopy

Data from four case-control studies support the effectiveness of flexible sigmoidoscopy in reducing colorectal cancer mortality\(^{[24–27]}\). Individuals in these studies who had undergone at least one screening sigmoidoscopy during the previous 10 years had only 21%–30% the risk of developing fatal colorectal cancer as control subjects. Compared with colonoscopy, flexible sigmoidoscopy is less expensive and has a lower complication rate (approximately 1–2 perforations per 10 000 examinations)\(^{[28,29]}\). In addition, it requires a less rigorous bowel preparation and does not require sedation. The major disadvantage of flexible sigmoidoscopy, however, is that it examines only a portion of the colon, thereby enabling detection of only approximately 50% of colonic lesions\(^{[30,31]}\). If a polyp is detected at sigmoidoscopy, colonoscopy may be needed to evaluate the entire colon, but the decision to perform colonoscopy should be individualized\(^{[9]}\). Factors associated with increased risk of advanced proximal neoplasia include age greater than 65 years, a family history of colorectal cancer, and distal adenomas that are ≥1 cm, multiple or contain villous histology\(^{[32–34]}\). In a randomized control trial, colonoscopy after detection of one or more polyps at screening sigmoidoscopy resulted in an 80% reduction in colorectal cancer incidence\(^{[35]}\). Nevertheless, proximal advanced adenomas (those ≥10 mm or containing villous histology, high-grade dysplasia or invasive cancer) also occur in approximately 2%–5% of individuals without distal adenomas\(^{[32–34,36]}\), underscoring the major limitation of screening sigmoidoscopy. A recent study of asymptomatic women who underwent screening colonoscopy showed that only 35% of those with advanced neoplasia would have had their lesions identified had they undergone flexible sigmoidoscopy alone\(^{[37]}\).

### Fecal occult blood testing combined with flexible sigmoidoscopy

The rationale for combining FOBT with flexible sigmoidoscopy is two-fold: (1) approximately half of the cancers missed by FOBT would be detected at sigmoidoscopy, and (2) FOBT is insensitive for detecting adenomas, many of which would be detected at sigmoidoscopy. Two randomized control trials have reported a 3–5-fold increase in the number of large adenomas and cancers detected when one time FOBT plus sigmoidoscopy are performed compared with one time FOBT alone\(^{[38,39]}\). Nevertheless, there is little direct evidence to support such a combined approach over annual or biennial FOBT, which is more sensitive than a one time test. Furthermore, a large number of colonic adenomas and carcinomas are not within the reach of the sigmoidoscope. Although some of these lesions would be detected when a positive sigmoidoscopy leads to a follow-up colonoscopy or barium enema, many of them would be missed, as up to 50% of proximal colonic cancers are not associated with a distal adenoma\(^{[34,40–44]}\). One study demonstrated that one-time screening with FOBT plus sigmoidoscopy failed to identify about one-quarter of subjects with advanced neoplasia and one half of subjects with advanced proximal neoplasia\(^{[44]}\).

### Colonoscopy

Colonoscopy is the only colorectal cancer screening test that allows evaluation of the entire colon and provides the opportunity to remove polyps and small polyloid cancers at the same time. Although there are no controlled trials demonstrating that screening colonoscopy alone reduces colorectal cancer incidence or mortality in those at average risk for the disease, indirect evidence for the effectiveness of colonoscopy comes from one case control study\(^{[29]}\) and several cohort and observational studies\(^{[45–48]}\). The case control study showed a 40%–50% reduction in colorectal cancer incidence in individuals who had undergone colonoscopy or polypectomy\(^{[29]}\). In addition, it is reasonable to extrapolate to colonoscopic screening the evidence of reduced colorectal cancer mortality shown with screening sigmoidoscopy\(^{[24,25]}\). Limitations of colonoscopy, however, are its greater cost and risk compared with other screening tests. Perforation occurs in approximately 1 in 1000 colonoscopies, major
bleeding occurs in approximately 3 per 1000, and 1–3 individuals in 10 000 undergoing colonoscopy die of complications from the procedure[28,41,49–51]. In addition, colonoscopy is incomplete in 5%–15% of individuals[40,41,49].

As stated previously, the advantage of colonoscopy over sigmoidoscopy is that approximately half of patients with advanced proximal neoplasms have no distal colonic neoplasms[33,34,37,52]. The rationale for the recommended 10-year interval for colonoscopic screening is based on the relatively high sensitivity of colonoscopy for polyp detection and the relatively long period of time required for most adenomatous polyps to transform into cancers, estimated to be at least 10 years, on average[53]. A study of back-to-back colonoscopies[54] and a study comparing colonoscopy and computed tomography colonography[55] have shown colonoscopy to have a sensitivity of 88%–94% for adenomas ≥1 cm.

Barium enema examination

For many years the double contrast barium enema (DCBE) was the only radiologic alternative to colonoscopy for colorectal cancer detection. Similar to colonoscopy, barium enema examination is a test that allows evaluation of the entire colon in approximately 90%–95% of patients[56–58]. No data are available on the sensitivity of DCBE in an average risk screening population. However, a screening study of patients at higher than average risk for colorectal neoplasia showed a 39%–56% sensitivity for polyps ≥1 cm for three independent readers[59]. The National Polyp Study in the United States demonstrated a sensitivity for DCBE of approximately 50% for ≥1 cm polyps in patients undergoing surveillance after removal of adenomatous polyps[60]. A study comparing colonoscopy, DCBE and computed tomography colonography reported a sensitivity of DCBE for ≥1 cm polyps of 45%[61].

In a non-randomized retrospective study of over 2000 consecutive patients with colorectal cancer in community practice, the sensitivity for cancer was 85% with DCBE and 95% with colonoscopy[62]. The major disadvantages of DCBE are its relatively low sensitivity for polyps ≥1 cm and the need for subsequent colonoscopy for polyp removal after a positive study. Its advantages compared to colonoscopy are that it is safer (approximately 1 perforation in 25 000 procedures)[63], less expensive, and does not require sedation.

Cost effectiveness

Most studies of the cost-effectiveness of FOBT (every 1–2 years), flexible sigmoidoscopy (every 5 years), colonoscopy (every 10 years) and double contrast barium enema examination (every 5–10 years) have shown costs per life-year saved of less than $25 000[64–68]. These figures compare favorably with estimates of cost per life-year saved for breast cancer, cervical cancer and hypertension screening programs, which range from approximately $9000–$50 000[69,70].

Screening recommendations (Table 1)

Recommended options for colorectal cancer screening of asymptomatic individuals of average risk include the following (beginning at age 50): annual FOBT (if positive, examine entire colon with colonoscopy or with sigmoidoscopy plus DCBE if colonoscopy is not available), flexible sigmoidoscopy every 5 years (followed by colonoscopy in most cases if adenomatous polyp or cancer found), annual FOBT and sigmoidoscopy every 5 years, colonoscopy every 10 years, or DCBE every 5 years.

| Table 1 Recommended options for colorectal cancer screening in asymptomatic, average-risk individuals[8–10] |
|---------------------------------------------------------------|
| **Starting at age 50:**                                        |
| Focal occult blood test (FOBT)a,b                             | Annual       |
| Flexible sigmoidoscopy                                        | Every 5 years|
| FOBT + sigmoidoscopy                                          | Annual and every 5 years |
| Colonoscopy                                                   | Every 10 years|
| Double contrast barium enema (DCBE)                          | Every 5 years|
| aUS Preventive Service Task Force: annual or biennial.        |
| bUS Agency for Health Care Policy and Research: without rehydration. |

High risk population

Individuals at increased risk for colorectal cancer are those with (1) a personal or family (first degree relative) history of colorectal cancer or adenoma, (2) longstanding ulcerative or Crohn’s colitis, or (3) a genetic predisposition to a hereditary polyposis or non-polyposis syndrome. Individuals with a single first-degree relative with colorectal cancer have a risk of developing colorectal cancer approximately 2–3 times that of the general population[71,72]. In addition, cancers tend to occur at an earlier age in this population. If the first-degree relative was diagnosed with colon cancer at or before the age of 50 years, or if more than one relative is affected, the risk is 3–4 times that of the general population[74]. Individuals with first-degree relatives with adenomas have an approximately two-fold increased risk of colorectal cancer[72–74]. Patients with long-standing ulcerative colitis are at increased risk for colorectal cancer, particularly those with pancolitis and early age of onset of their disease[75]. Colorectal cancer in this group of patients is thought to develop in areas of mucosal dysplasia. Patients with longstanding Crohn’s colitis have a similar increased risk of colorectal cancer[9]. Familial adenomatous polyposis coli (FAP) is a disease that results from inherited or acquired defects in
be associated with extracolonic neoplasms a young age, are often located in the right colon, and may to multiple cancers. The colon cancers typically occur at dominant disorder that results in a familial predisposition polyposis colorectal cancer (HNPCC) is an autosomal cancer if the colon is not removed. Hereditary non-
the colon, which results in a 100% risk of colorectal with this disease develop numerous polyps throughout the APC gene located on the fifth chromosome. Patients with this disease develop numerous polyps throughout the colon, which results in a 100% risk of colorectal cancer if the colon is not removed. Hereditary non-polypsis colorectal cancer (HNPPC) is an autosomal dominant disorder that results in a familial predisposition to multiple cancers. The colon cancers typically occur at a young age, are often located in the right colon, and may be associated with extracolonic neoplasms. For individuals with a first-degree relative with a colorectal cancer or adenomatous polyp diagnosed at age ≥60 years or two second-degree relatives with colorectal cancer, the screening recommendations are the same as for the average risk population, except that screening should begin at age 40 (Patients with a personal history of colorectal cancer or adenomatous polyp are not included in this discussion, as they fall under the category of surveillance rather than screening). For individuals with two or more first-degree relatives with colon cancer, or a single first-degree relative with colon cancer or adenomatous polyp diagnosed before the age of 60 years, colonoscopy is recommended every 5 years, beginning at age 40 or 10 years earlier than the youngest age of colon cancer diagnosis in the family, whichever comes first. The recommendation for patients at risk for FAP is to receive genetic counseling (and possibly genetic testing) and to undergo flexible sigmoidoscopy annually beginning at age 10–12 years. Patients with a variant of FAP called attenuated APC (AAPC) have a tendency toward right-sided adenomatous polyps and development of cancer approximately 10 years later than those with the usual form of FAP. For this group, colonoscopy should be used rather than sigmoidoscopy, and screening should begin in the late teens or early 20s. The recommendation for patients with HNPCC is to receive genetic counseling (and possibly genetic testing) and to undergo colonoscopy every 1–2 years beginning at age 20–25 years, or 10 years younger than the earliest colorectal cancer diagnosis in the family, whichever comes first. The recommendation for patients with longstanding ulcerative colitis and Crohn’s colitis is to undergo colonoscopy with biopsies looking for dysplasia every 1–2 years beginning 8 years after diagnosis. One case-control study demonstrated reduced mortality from colorectal cancer among ulcerative colitis patients in colonoscopic surveillance programs.

### Screening recommendations (Table 2)

| First-degree relative with colorectal cancer or adenomatous polyp at age ≥60 years, or 2 second-degree relatives with colorectal cancer | Same as for average risk individual, but begin at age 40 |
| Two or more first-degree relatives with colorectal cancer, or a single first-degree relative with colorectal cancer or adenomatous polyps diagnosed at age <60 years | Colonoscopy every 5 years, beginning at age 40 years or 10 years younger than the earliest colorectal cancer diagnosis in the family, whichever comes first |
| One second-degree or any third-degree relative with colorectal cancer | Same as for average risk individual |
| Family history of FAP | Annual flexible sigmoidoscopy beginning at age 10–12 years if gene carrier or indeterminate |
| Family history of HNPPC | Colonoscopy every 1–2 years, beginning at age 20–25 years, or 10 years younger than the earliest colorectal cancer diagnosis in the family, whichever comes first |
| History of inflammatory bowel disease (ulcerative colitis or Crohn’s colitis) | Consider colonoscopy surveillance for dysplasia every 1–2 years beginning after 8 years of disease |

**Note:**
- First-degree relatives include parents, siblings, and children.
- Second-degree relatives include grandparents, aunts, and uncles.
- Third-degree relatives include great-grandparents and cousins.
- Includes the subcategories of familial adenomatous polyposis, Gardner syndrome, some Turcot syndrome families, and AAPC.
- In AAPC, colonoscopy should be used instead of sigmoidoscopy because of the preponderance of proximal colonic adenomas. Colonoscopy screening in AAPC should probably begin in the late teens or early 20s.

**Modified from Winawer et al.**

**New and emerging technologies**

**Computed tomographic colonography**

Computed tomographic colonography (CTC) (also known as ‘virtual colonoscopy’) was introduced in 1994 as a non-invasive method of imaging the colon using helical CT. Although CTC has been shown to be useful for certain clinical indications, it has not yet been endorsed as a colorectal cancer screening test and is not covered by most third-party payers when used for screening purposes. This examination is performed by acquiring a volumetric data set of the abdomen and pelvis with helical CT after insufflation of the colon with carbon dioxide or air. The colon can then be viewed with either 2-dimensional or 3-dimensional techniques. The 3-dimensional visualization technique provides a
perspective that simulates colonoscopic navigation of the colonic lumen.

Except for one study that was hampered by suboptimal technique and a steep learning curve\cite{83}, early CTC trials performed with single detector-row CT scanners demonstrated sensitivities of 68%–92% and specificities of 82%–98% for polyps $\geq 1 \text{ cm}^{[84-90]}$. A meta-analysis of these early trials confirmed reasonably high pooled sensitivities by patient and by lesion of 88% and 81%, respectively, with a pooled specificity of 95% for polyps $\geq 1 \text{ cm}^{[91]}$. More recent studies performed with 4-detector row scanners have demonstrated sensitivities and specificities of 82%–100% and 90%–98%, respectively for polyps $\geq 1 \text{ cm}^{[92-95]}$. It is important to recognize, however, that these trials were not performed on screening populations but on individuals who were at increased risk for colorectal neoplasia. A large single institution screening trial using single detector-row CT demonstrated individual reader sensitivities of 59%–73% and specificities of 95%–98% for polyps $\geq 1 \text{ cm}^{[59]}$. A smaller single institution screening trial using multidetector-row CT demonstrated a sensitivity of 100% for polyps $\geq 1 \text{ cm}$, but in that study only three patients had polyps of that size\cite{96}.

One large multicenter trial comparing multidetector-row CTC and fiberoptic colonoscopy for detecting polyps in patients undergoing colorectal cancer screening has been published\cite{55}. In that study, the sensitivities of CTC and colonoscopy for adenomatous polyps $\geq 1 \text{ cm}$ were 94% and 88%, respectively. Thus, in that trial, CTC outperformed optical colonoscopy. However, two multicenter trials in which patients with clinical indications for colonoscopy were evaluated with CTC showed sensitivities for polyps $\geq 1 \text{ cm}$ of only 55% and 59%\cite{61,97}. One of these latter studies\cite{97} suffered from inadequate reader training and both used technology that was somewhat outdated.

CTC has a number of potential advantages compared with conventional fiberoptic colonoscopy. It is a non-invasive technique, requires no sedation, can be completed in a much shorter time, and is associated with a lower risk of complications. The only study of morbidity related to CTC reported to date has demonstrated a perforation rate of 3 in 7180 studies (0.04%)\cite{98}. No deaths related to CTC have been reported. In addition, CTC has the potential to eliminate some of the blind spots that can be problematic with conventional colonoscopy. Moreover, because the CTC examination is not limited to the colon, it is capable of demonstrating clinically important extracolonic abnormalities\cite{99-103}. An additional potential advantage of CT colonography is the possibility of avoiding rigorous bowel preparation through the use of stool and fluid tagging. A study of CTC without cathartic preparation in over 200 patients demonstrated a sensitivity of 95.5% for polyps 8 mm and larger\cite{104}.

On the other hand, CTC has some disadvantages compared to colonoscopy. CTC does not allow biopsy or removal of polyps that are identified, and it requires the use of ionizing radiation. In addition, the sensitivity of CTC for detecting clinically significant polyps has varied considerably in the clinical trials published to date.

**Immunochemoical FOBT**

Immunochemoical fecal occult blood tests use monoclonal and/or polyclonal antibodies that detect the intact globin protein portion of human hemoglobin\cite{105}. Whereas guaiac-based tests can yield false-positive results if certain foods (meats, some raw fruits and vegetables), vitamins (vitamin C or high levels of foods containing vitamin C) or drugs (aspirin) are ingested in the days before taking the test\cite{19-21}, immunochemoical FOBTs do not react with non-human hemoglobin or with uncooked fruits or vegetables that may contain peroxidase activity. Thus, immunochemoical FOBT has the potential not only to improve specificity, but possibly to increase patient compliance because of the lack of dietary restrictions. In addition, because globin does not survive passage through the upper gastrointestinal tract, the test is specific for bleeding in the colon and rectum\cite{106}. Nevertheless, immunochemoical FOBT has limitations similar to guaiac-based FOBT related to the intermittency of bleeding from colorectal adenomas and cancers.

**Fecal DNA**

DNA is shed continuously from the gastrointestinal tract, is stable in stool, and can be detected in minute amounts through use of amplification tests, such as polymerase chain reaction\cite{107}. Because many DNA mutations associated with colorectal carcinogenesis have been characterized, identification within stool of DNA containing these mutations may be a way of identifying individuals with pre-clinical and clinical disease\cite{108}. Studies of fecal DNA testing in patients with advanced, symptomatic colorectal lesions have reported sensitivities of 62%–91% for cancer and 27%–82% for advanced adenomas\cite{108-112}. However, a large-scale multi-center study involving asymptomatic, average risk individuals showed that although fecal DNA testing was more sensitive than guaiac-based FOBT, it detected only 18% of subjects with advanced neoplasia and only 52% of those with invasive carcinoma\cite{113}. Thus, further marker discovery and technological refinements will be necessary to improve test performance\cite{114}. Nevertheless, stool-based molecular approaches to colorectal cancer screening hold great promise.

**Video capsule endoscopy**

The capsule video endoscope is a pill that contains a camera and is small enough to be swallowed. Developed
by an Israeli company (Given Imaging Ltd.), the capsule records multiple images per second as it passes through the gastrointestinal tract. The images are recorded on a portable data recorder worn on a belt and are reviewed as a video. Clinical studies of this device thus far have been limited to the stomach and small bowel. Extending the capsule endoscopy examination to the colon would require that the capsule have a longer battery life. In addition, a formal cathartic bowel preparation as for colonoscopy would be required.

**Conclusion**

Although colorectal cancer screening has been shown to reduce mortality from colorectal cancer, patient compliance with screening recommendations remains poor. Obstacles to colorectal cancer screening compliance include the inconvenience, invasiveness and unpleasantness of some of the tests and their preparations. Newer technologies such as stool-based DNA analysis and computed tomographic colonography (‘virtual colonoscopy’) hold great promise not only for improving detection of colorectal cancer and adenomatous polyps but also for improving compliance with colorectal cancer screening recommendations.

**References**

[1] The cancer atlas. In: Chapter 11, Major Cancers, Mackay J, Jemal A, Lee NC, Parkin DM, eds. Brighton, UK: American Cancer Society, Myriad Editions Limited, 2006: 44–5.
[2] Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30.
[3] Bond JH. Screening guidelines for colorectal cancer. Am J Med 1999; 106: 7S–10S: 75–105.
[4] Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89: 1406–23.
[5] Trends in screening for colorectal cancer—United States. 1997 and 1999. MMWR 2001; 50: 162–6.
[6] Seeff LC, Nadel MR, Klubunde CN et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004; 100: 2093–103.
[7] Subramanian S, Amokar MM, Hunt TL. Use of colonoscopy for colorectal cancer screening: evidence from the 2000 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2005; 14: 409–16.
[8] Smith RA, Cokkinides V, Eyer HJ. American Cancer Society Guidelines for Early Detection of Cancer, 2003. CA Cancer J Clin 2003; 53: 27–43.
[9] Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology 2003; 124: 544–60.
[10] Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 132–41.
[11] Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365–71.
[12] Kronborg O, Fenger C, Olsen J et al. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467–71.
[13] Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472–7.
[14] Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434–7.
[15] Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 1997; 89: 1423–28.
[16] Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 1999; 91: 1641–6.
[17] Ahlquist DA, Wianed HS, Moertel CG et al. Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemocult and HemoQuant tests. JAMA 1993; 269: 1262–7.
[18] Allison JE, Tekawa IS, Ransom LJ et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155–9.
[19] Smith RA, von Eschenbach AC, Wender R et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001—testing for early lung cancer detection. CA Cancer J Clin 2001; 51: 38–75.
[20] Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians (see comments). Ann Intern Med 1997; 126: 811–22.
[21] American College of Physicians. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med 1997; 126: 808–10.
[22] Young GP, St John JB, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. A WHO and OMERD Report. Am J Gastroenterol 2002; 97: 2499–507.
[23] Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med 1996; 334: 155–9.
[24] Selby JV, Friedman GD, Quesenberry CPJ et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653–7.
[25] Newcomb PA, Norfleet RG, Storer BE et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 1572–5.
[26] Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155: 1741–8.
[27] Kavanagh AM, Giovannucci EL, Fuchs CS, Colditz GA. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998; 9: 455–62.

[28] Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594–642.

[29] Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy: a case-control study of 32,702 veterans. Ann Intern Med 1995; 123: 904–10.

[30] Selby JV, Friedman GD. US preventative task force. Sigmoidoscopy in the periodic health examination of asymptomatic adults. JAMA 1989; 261: 594–601.

[31] Selby JV, Friedman GD, Collen MF. Sigmoidoscopy and mortality from colorectal cancer: the Kaiser Permanente Multiphasic Evaluation study. J Clin Epidemiol 1988; 41: 427–34.

[32] Levin TR, Palitz A, Grossman S et al. Predicting advanced proximal colonic neoplasiap with screening sigmoidoscopy. JAMA 1999; 281: 1611–17.

[33] Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162–8.

[34] Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169–74.

[35] Thiis-Evensen E, Hoff GS, Sauer J et al. Population based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Scand J Gastroenterol 1999; 34: 414–20.

[36] Farraye FA, Wallace M. Clinical significance of small polyps found during screening with flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 2002; 12: 41–51.

[37] Schoenfeld P, Cash B, Flood A et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352: 2061–8.

[38] Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997; 84: 1274–6.

[39] Rasmussen M, Kronborg O, Fenger C, Jørgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999; 34: 73–8.

[40] Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991; 86: 1775–80.

[41] Rex DK, Lehman GA, Haves RH et al. Screening colonoscopy in symptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 1991; 100: 64–7.

[42] Kadakia SC, Wroblewski CS, Kadakia AS et al. Prevalence of or proximal colonic polyps in average-risk asymptomatic patients with negative fecal occult blood test and flexible sigmoidoscopy. Gastrointest Endosc 1996; 44: 112–17.

[43] Lemmel TG, Haseman JH, Rex DK et al. Neoplasia distal to the splenic flexure in patients with proximal colon cancer. Gastrointest Endosc 1996; 44: 109–11.

[44] Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555–60.

[45] Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonscopic polypectomy. N Engl J Med 1993; 329: 1977–81.

[46] Jørgensen OD, Kronborg O, Fenger C. The Funen adenoma follow-up study: Incidence and death from colorectal carcinoma in an adenoma surveillance program. Scand J Gastroenterol 1993; 28: 869–74.

[47] Rex DK. Colonoscopy: A review of its yield for cancer and adenomas by indication. Am J Gastroenterol 1995; 3: 353–65.

[48] Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. The Italian Multicentre Study Group. Efficacy in standard clinical practice of colonscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812–15.

[49] Godreau CJ. Office-based colonoscopy in a family practice. Fam Pract Res J 1992; 12: 313–20.

[50] Jentschura D, Raute M, Winter J et al. Complications in endoscopy of the lower gastrointestinal tract: therapy and prognosis. Surg Endosc 1994; 8: 672–6.

[51] Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15: 347–51.

[52] Levin TR, Palitz A, Grossman S et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999; 281: 1611–17.

[53] Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162–8.

[54] Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169–74.

[55] Thiis-Evensen E, Hoff GS, Sauer J et al. Population based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Scand J Gastroenterol 1999; 34: 414–20.

[56] Farraye FA, Wallace M. Clinical significance of small polyps found during screening with flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 2002; 12: 41–51.

[57] Schoenfeld P, Cash B, Flood A et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352: 2061–8.

[58] Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997; 84: 1274–6.

[59] Rasmussen M, Kronborg O, Fenger C, Jørgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999; 34: 73–8.

[60] Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991; 86: 1775–80.

[61] Rex DK, Lehman GA, Haves RH et al. Screening colonoscopy in symptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 1991; 100: 64–7.

[62] Kadakia SC, Wroblewski CS, Kadakia AS et al. Prevalence of or proximal colonic polyps in average-risk asymptomatic patients with negative fecal occult blood test and flexible sigmoidoscopy. Gastrointest Endosc 1996; 44: 112–17.
[61] Rockey DC, Paulson E, Niedzwiecki D et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005; 365: 305–11.

[62] Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997; 112: 17–23.

[63] Blakeborough A, Sheridan MB, Chapman AH. Complications of barium enema examinations: a survey of UK consultant radiologists 1992–1994. Clin Radiol 1992; 52: 142–8.

[64] Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Prevention and Early Detection of Colorectal Cancer, Young G, Levin B, eds. London: Saunders, 1996.

[65] Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 1954–61.

[66] Leeve F, Brown ML, Boer R, van Balleghoef M, van Oortmarssen GJ, Hubbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000; 92: 557–63.

[67] Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 573–84.

[68] Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US preventive services task force. Ann Intern Med 2002; 132: E96–106.

[69] Garber AM, Phelps CE. Economic foundation of cost-effectiveness analysis. J Health Econ 1997; 16: 1–31.

[70] Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993; 25: 113–18.

[71] Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992–3003.

[72] Burt RW. Colon cancer screening. Gastroenterology 2000; 119: 837–53.

[73] Ahsan H, Neugut AI, Garbowsky CG et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128: 900–5.

[74] Winawer SJ, Zauber AG, Gerdies H et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334: 82–7.

[75] Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228–33.

[76] Vaseen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary non-polyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020–7.

[77] Giardiello FM, Brensinger JD, Luce MC et al. Phenotypic expression of disease in families that have mutations in the 5′ region of the adenomatous polyposis coli gene. Ann Intern Med 1997; 126: 514–19.

[78] Brensinger JD, Laken SJ, Luce MC et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 1998; 43: 548–52.

[79] Gardner RJ, Kool D, Edkins E et al. The clinical correlates of a 3′ truncating mutation (codons 1982–1983) in the adenomatous polyposis coli gene. Gastroenterology 1997; 113: 326–31.

[80] Soravia C, Berk T, Madlensky L et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62: 1290–301.

[81] Choi PM, Nugent FW, Schoetz DJJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418–24.

[82] Vining DJ, Gelfand DW. Noninvasive colonoscopy using helical CT scanning, 3D reconstruction, and virtual reality. Presented at the 23rd Annual Meeting and Postgraduate Course of the Society of Gastrointestinal Radiologists, Maui, Hawaii, 1994.

[83] Rex DK, Vining D, Kopecky KK. An initial experience with screening for colon polyps using spiral CT with and without CT colonography (virtual colonoscopy). Gastrointest Endosc 1999; 50: 309–13.

[84] Hara AK, Johnson CD, Reed JE et al. Detection of colorectal polyps with CT colonography: initial assessment of sensitivity and specificity. Radiology 1997; 205: 59–65.

[85] Fenlon HM, Nunes DP, Schroy PC, Barish MA, Clarke PD, Ferrucci JT. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N Engl J Med 1999; 341: 1496–542.

[86] Kay CL, Kulling D, Hawes RH, Young JWR, Cotton PB. Virtual endoscopy—comparison with colonoscopy in the detection of space-occupying lesions of the colon. Endoscopy 2000; 32: 226–32.

[87] Yee J, Akerkar GA, Hung RK, Steinauer-Gebauer AM, Wall SD, McQuaid KR. Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. Radiology 2001; 219: 685–92.

[88] McFarland EG, Pilgram TK, Brink JA et al. CT colonography: multiserver diagnostic performance. Radiology 2002; 225: 380–90.

[89] Laghi A, Iannaccone R, Carbone I et al. Detection of colorectal lesions with virtual computed tomographic colonography. Am J Surg 2002; 183: 124–31.

[90] Pineau BC, Paskett EK, Chen GJ et al. Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps. Gastroenterology 2003; 125: 304–10.

[91] Sosna J, Morrin MM, Kruskal JB, Lavin PT, Rosen MP, Raptopoulos V. CT colonography of colorectal polyps: a meta analysis. AJR 2003; 181: 1593–8.

[92] Gluecker T, Dorta G, Keller W, Jornod P, Meuli R, Schnyder P. Performance of multidetector computed tomography colonography compared with conventional colonoscopy. Gut 2002; 51: 207–11.

[93] Macari M, Bini EJ, Xue X et al. Colorectal neoplasms: prospective comparison of thin-section low-dose multi-detector row CT colonography and conventional colonoscopy for detection. Radiology 2002; 224: 383–92.
Iannaccone R, Laghi A, Catalano C et al. Detection of colorectal lesions: lower-dose multi-detector row helical CT colonography compared with conventional colonoscopy. Radiology 2003; 229: 775–81.

Petersen BG, Christiansen TEM, Bjerregaard NC, Ljungmann K, Laurberg S. Colonoscopy and multidetector-array computed-tomographic colonography: detection rates and feasibility. Endoscopy 2003; 35: 736–42.

Macari M, Bini EJ, Jacobs SL et al. Colorectal polyps and cancers in asymptomatic average-risk patients: evaluation with CT colonography. Radiology 2004; 230: 629–36.

Cotton PB, Durkalski VL, Pineau BC et al. Computed tomographic colonography (virtual colonoscopy). A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004; 291: 1713–19.

Bar-Meir E, Amitai M, Blachar A, Peled N, Bar-Ziv J. Assessment of the risk of perforation at CT colonography. Presented at the 90th Scientific Assembly and Annual Meeting of Radiological Society of North America, Chicago, IL; November 26–December 3, 2004.

Hara AK, Johnson CD, MacCarty RL, Welch TJ. Incidental extracolonic findings at CT colonography. Radiology 2000; 215: 353–7.

Edwards JT, Wood CJ, Mendelson RM, Forbes GM. Extracolonic findings at virtual colonoscopy: implications for screening programs. Am J Gastroenterol 2001; 96: 3009–12.

Gluecker TM, Johnson CD, Wilson LA et al. Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. Gastroenterology 2003; 124: 911–16.

Ginnerup Pedersen B, Rosenkilde M, Christiansen TE, Laurberg S. Extracolonic findings at computed tomography colonography are a challenge. Gut 2003; 52: 1744–7.

Hellström M, Svensson MH, Lasson A. Extracolonic and incidental findings on CT colonography (virtual colonoscopy). AJR 2004; 182: 631–8.

Iannaccone R, Laghi A, Catalano C et al. Computed tomographic colonography without cathartic preparation for the detection of colorectal polyps. Gastroenterology 2004; 127: 1300–11.

Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA A Cancer J Clin 2003; 53: 44–55.

Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol 1999; 94: 344–50.

Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315: 157–68.

Ahlquist DA, Skoletsky JB, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219–27.

Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858–65.

Syngal S, Chung D, Willet C et al. The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment. Gastroenterology 2003; 124 (Suppl 1): A–5 (abstract).

Tagore KS, Lawson MJ, Yucaitis JA et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47–53.

Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311–20.

Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704–14.

Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128: 192–206.

Gay G, Delvauz M, Rey J-F. The role of video capsule endoscopy in the diagnosis of digestive diseases: a review of current possibilities. Endoscopy 2004; 36: 913–20.